Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Reference94 articles.
1. Yu H, MacIsaac D, Wong JJ, Sellers ZM, Wren AA, Bensen R et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47:364–370.
2. Van Der Valk ME, Mangen MJJ, Severs M, Van Der Have M, Dijkstra G, Van Bodegraven AA et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11:1–11.
3. Vasudevan A, Ip F, Liew D, Van Langenberg DR. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn’s Disease in the Biosimilar Era. Inflamm Bowel Dis. 2020;26:369–379.
4. Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A et al. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ. 2021;24:279–290.
5. Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K et al. The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020;26:1–10.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献